sur Jaguar Health, Inc. (NASDAQ:JAGX)
Magdalena Biosciences to Present at BIO Investor Forum
Magdalena Biosciences, a joint venture between Jaguar Health and Filament Health, will present at the BIO Investor Forum on October 16, 2024, in San Francisco. Dr. Karen Brunke, Acting CEO of Magdalena, will discuss the progress of MB2500, a psychoactive drug candidate targeting ADHD and schizophrenia cognitive deficits. The company plans to submit an IND application to the FDA in early 2025.
MB2500 is derived from a well-characterized plant known for neuroprotective properties. Magdalena, 40% owned by Jaguar, is focused on plant-based mental health treatments, with potential IND applications for more candidates in 2025.
The ADHD market is valued at $25 billion globally, while schizophrenia affects 1% of the U.S. population, with its market projected to grow significantly. The BIO Investor Forum seeks to advance therapeutic technologies into commercialization.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Jaguar Health, Inc.